Evidence map›Paper›PMID 28088871›Full record

ArticleIntegrative cancer therapies2018

Herbal Medicine Practices of Patients With Liver Cancer in Peru: A Comprehensive Study Toward Integrative Cancer Management.

Teresa Rojas Rojas, Geneviève Bourdy, Eloy Ruiz, Juan-Pablo Cerapio, Pascal Pineau, Jacques Gardon, Franco Doimi, Xavier Deparis, Eric Deharo, Stéphane Bertani

Open access · goldAbstract read
In one paragraph

Article in Integrative cancer therapies, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 33 citations in OpenAlex.

  1. A Review onCancers · 2022
    Review
  2. Observational
  3. Review
  4. Histopathological evaluation ofVeterinary world · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Teresa Rojas Rojas1 Aix-Marseille Université, IRD, INSERM, UMR 912, Marseille, France.
Geneviève Bourdy2 Université de Toulouse, IRD, UPS, UMR 152, Toulouse, France.
Eloy Ruiz3 Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
Juan-Pablo Cerapio4 Sorbonne Universités, UPMC Univ Paris 06, Institut Pasteur, Paris, France.
Pascal Pineau5 Institut Pasteur, Paris, France.
Jacques Gardon7 Université de Montpellier, IRD, CNRS, UMR 5569, Montpellier, France.
Franco Doimi3 Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
Xavier Deparis1 Aix-Marseille Université, IRD, INSERM, UMR 912, Marseille, France.
Eric Deharo2 Université de Toulouse, IRD, UPS, UMR 152, Toulouse, France.
Stéphane Bertani2 Université de Toulouse, IRD, UPS, UMR 152, Toulouse, France.
Institut de Recherche pour le Développement · FRInstituto Nacional de Enfermedades Neoplásicas · PEAix-Marseille Université · FRInserm · FRInstitut Pasteur · FRUniversité Fédérale de Toulouse Midi-Pyrénées · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleThe highest burden of liver cancer occurs in developing countries, where the use of herbal medicine (HM) is still widespread. Despite this trend, few studies have been conducted to report HM practices of patients with a hepatic tumor in the developing world. Hence, this study aimed to document the use of HM among patients with liver cancer in Peru. STUDY DESIGN AND

methodsA comparative behavioral epidemiological survey was conducted among liver cancer patients attending the National Cancer Institute of Peru. Information was obtained by direct interviews based on a semistructured questionnaire. The use of HM in Peruvian liver cancer patients was reported, first, regarding general consumption prior to the onset of disease, and second, after the appearance of symptoms that patients would relate to their tumor. In parallel, general consumption of HM in noncancerous people was assessed as a comparative figure. A correspondence analysis was performed to reveal potential associations between the symptoms of cancer and the specific use of HM.

resultsEighty-eight patients and 117 noncancerous individuals participated in the survey. Overall, 68.3% of the people interviewed claimed to use HM on a regular basis for general health preservation. Furthermore, 56.8% of the patients turned to plants first to treat the disorders for which they later came to the cancer care center. When compared with the number of plant species used routinely (n = 78), a selection of plants was made by patients in response to the symptoms of cancer (n = 46). At least 2 plant species, Aloe vera and Morinda citrifolia, were significantly associated with the treatment of liver cancer-related symptoms in the patient group.

conclusionsThe present study is the first survey on the HM practices of patients with liver cancer in Latin America and, more broadly, in the developing world. Our findings confirm that HM remains one of the principal primary health care resources in Peru, even for a severe disease like liver cancer. These traditional, complementary and alternative medicine practices should be taken into consideration in Peruvian health programs aiming to educate the population in cancer prevention and treatment, as well as integrative cancer management.

Indexed as

PhytotherapyAdultComplementary TherapiesFemaleHealth Care SurveysHerbal MedicineHumansIntegrative MedicineIntegrative OncologyLiver NeoplasmsMaleMiddle AgedPeruProfessional PracticeYoung Adultbehavioral epidemiological surveycancercomplementary and alternative medicinedeveloping worldethnobotanyIndigenous peopleintegrative medicineLatin Americaliver diseasetraditional medicine

Identifiers

PMID28088871
PMCPMC5950939
OpenAlexW2571581217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.